NYSEAMERICAN:PTN Palatin Technologies (PTN) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PTN Stock Alerts $1.84 +0.24 (+15.00%) (As of 11:51 AM ET) Add Compare Share Share Today's Range$1.61▼$1.8650-Day Range N/A52-Week Range$1.43▼$5.65Volume213,291 shsAverage Volume532,483 shsMarket Capitalization$29.70 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Palatin Technologies alerts: Email Address Palatin Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside969.2% Upside$17.00 Price TargetShort InterestBearish9.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingSelling Shares$23,400 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.36) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Palatin Technologies has a forecasted upside of 969.2% from its current price of $1.59.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.39% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palatin Technologies has recently increased by 25.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 1.4 News and Social Media Coverage News SentimentPalatin Technologies has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Palatin Technologies this week, compared to 2 articles on an average week.Search InterestOnly 26 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,400.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 11.50% of the stock of Palatin Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Palatin Technologies are expected to grow in the coming year, from ($2.36) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalatin Technologies has a P/B Ratio of 159.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Palatin Technologies Stock (NYSEAMERICAN:PTN)Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.Read More PTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTN Stock News HeadlinesMarch 17, 2024 | insidertrades.comPalatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Robert K. Deveer, Jr. Sells 11,700 SharesMarch 23, 2024 | americanbankingnews.comPalatin Technologies (NYSEAMERICAN:PTN) Stock Price Passes Above 200-Day Moving Average of $0.00March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 15, 2024 | finance.yahoo.comPTN Apr 2024 2.500 putMarch 15, 2024 | finance.yahoo.comPTN Apr 2024 7.500 callMarch 14, 2024 | msn.comPalatin files to sell 1.92M shares of common stock for holdersFebruary 29, 2024 | markets.businessinsider.comMaintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future ProspectsFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)March 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)February 28, 2024 | msn.comPalatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock PlummetsFebruary 28, 2024 | finanznachrichten.dePalatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 28, 2024 | marketwatch.comPalatin Technologies Shares Tumble Premarket on Dry-Eye Study ResultsFebruary 28, 2024 | finance.yahoo.comPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 28, 2024 | prnewswire.comPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 21, 2024 | finance.yahoo.comPalatin Technologies, Inc. (PTN)February 16, 2024 | markets.businessinsider.comBuy Rating Affirmed on Palatin Technologies for Promising Pipeline and Strategic Market PositioningFebruary 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Palatin Technologies Amid Promising Clinical Trials and Robust Financial PositionFebruary 16, 2024 | finance.yahoo.comPalatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call TranscriptFebruary 16, 2024 | benzinga.comPalatin Techs Stock (AMEX:PTN), Quotes and News SummaryFebruary 16, 2024 | finance.yahoo.comQ2 2024 Palatin Technologies Inc Earnings CallFebruary 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for Palatin Technologies Backed by Strong Clinical Pipeline and Strategic InitiativesFebruary 15, 2024 | finanznachrichten.dePalatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateFebruary 15, 2024 | finance.yahoo.comPalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateFebruary 15, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in February 2024February 15, 2024 | prnewswire.comPalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateFebruary 9, 2024 | finance.yahoo.comPalatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024See More Headlines Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees34Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+969.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,540,000.00 Net Margins-445.12% Pretax Margin-503.33% Return on Equity-583.06% Return on Assets-184.90% Debt Debt-to-Equity Ratio0.34 Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$4.85 million Price / Sales5.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book159.00Miscellaneous Outstanding Shares16,140,000Free Float14,894,000Market Cap$25.66 million OptionableNot Optionable Beta0.94 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Carl Spana Ph.D. (Age 62)Co-Founder, President, CEO & Director Comp: $979kMr. Stephen T. Wills CPA (Age 67)MST, CFO, COO, Executive VP, Treasurer & Secretary Comp: $910.55kBurns McClellanVice President of Investor RelationsMr. Stephen A. Slusher Esq.Chief Legal OfficerDr. Michael B. Raizman M.D.Chief Medical OfficerMr. James E. Hattersley (Age 64)Senior Vice President of Business Development Mr. John Dodd Ph.D.Senior Vice President of Preclinical DevelopmentMr. Robert JordanSenior Vice President of Program OperationsMore ExecutivesKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSEMEI PharmaNASDAQ:MEIPLisata TherapeuticsNASDAQ:LSTAPharmaxisOTCMKTS:PXSLYIGC PharmaNYSEAMERICAN:IGCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 166,071 shares on 3/11/2024Ownership: 3.399%Robert K Deveer JrSold 11,700 sharesTotal: $23,400.00 ($2.00/share)Vanguard Group Inc.Bought 166,071 shares on 2/15/2024Ownership: 3.993%Citadel Advisors LLCBought 2,400 shares on 2/15/2024Ownership: 0.000%Armistice Capital LLCBought 590,000 shares on 2/13/2024Ownership: 4.294%View All Insider TransactionsView All Institutional Transactions PTN Stock Analysis - Frequently Asked Questions Should I buy or sell Palatin Technologies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks. What is Palatin Technologies' stock price target for 2024? 1 brokers have issued 1-year price objectives for Palatin Technologies' stock. Their PTN share price targets range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 969.2% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts. How have PTN shares performed in 2024? Palatin Technologies' stock was trading at $4.00 at the beginning of the year. Since then, PTN stock has decreased by 60.3% and is now trading at $1.59. View the best growth stocks for 2024 here. Are investors shorting Palatin Technologies? Palatin Technologies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 25.0% from the February 29th total of 1,160,000 shares. Based on an average daily trading volume, of 552,700 shares, the short-interest ratio is presently 2.6 days. Approximately 9.4% of the shares of the company are sold short. View Palatin Technologies' Short Interest. When is Palatin Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PTN earnings forecast. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to analyst estimates of $2.28 million. Palatin Technologies had a negative net margin of 445.12% and a negative trailing twelve-month return on equity of 583.06%. During the same quarter last year, the business posted ($0.13) EPS. When did Palatin Technologies' stock split? Palatin Technologies's stock reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM). Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.29%), Vanguard Group Inc. (3.40%), Vanguard Group Inc. (3.99%), Northern Trust Corp (0.18%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton, Robert K Deveer Jr and Stephen T Wills. View institutional ownership trends. How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:PTN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.